The New York Times, February 7, 2021

Link

A more contagious variant of the coronavirus first found in Britain is spreading rapidly in the United States, doubling roughly every 10 days, according to a new study.

Analyzing half a million coronavirus tests and hundreds of genomes, a team of researchers predicted that in a month this variant could become predominant in the United States, potentially bringing a surge of new cases and increased risk of death.

The new research offers the first nationwide look at the history of the variant, known as B.1.1.7, since it arrived in the United States in late 2020. Last month, the Centers for Disease Control and Prevention warned that B.1.1.7 could become predominant by March if it behaved the way it did in Britain. The new study confirms that projected path.

“Nothing in this paper is surprising, but people need to see it,” said Kristian Andersen, a co-author of the study and a virologist at the Scripps Research Institute in La Jolla, Calif. “We should probably prepare for this being the predominant lineage in most places in the United States by March.”

Continue reading “Virus Variant First Found in Britain Now Spreading Rapidly in U.S.”

The New York Times, February 5, 2021 (with Isabel Kershner)

Link

In the most extensive real-world test so far, Israel has demonstrated that a robust coronavirus vaccination program can have a quick and powerful impact, showing the world a plausible way out of the pandemic.

Cases of Covid-19 and hospitalizations dropped dramatically among people who were vaccinated within just a few weeks, according to new studies in Israel, where a rapid vaccine rollout has made it a kind of test laboratory for the world. And early data suggests that the vaccines are working nearly as well in practice as they did in clinical trials.

“We say with caution, the magic has started,” tweeted Eran Segal, a quantitative biologist at the Weizmann Institute of Science and co-author of a new study on the vaccine’s impact in Israel.

Continue reading “Israel’s Vaccination Results Point a Way Out of Virus Pandemic”

The New York Times, February 1, 2021

Link

A fast-spreading coronavirus variant first observed in Britain has gained a worrisome mutation that could make it harder to control with vaccines, Public Health England reported on Monday. And on Tuesday, a team of researchers reported an experiment suggesting that this mutation might make vaccines somewhat less effective against the variant.

Continue reading “A study shows the variant spreading rapidly in Britain might make vaccines less effective”

The New York Times, January 30, 2021

Link

Nearly a year into the coronavirus pandemic, as thousands of patients are dying every day in the United States and widespread vaccination is still months away, doctors have precious few drugs to fight the virus.

A handful of therapies — remdesivir, monoclonal antibodies and the steroid dexamethasone — have improved the care of Covid patients, putting doctors in a better position than they were when the virus surged last spring. But these drugs are not cure-alls and they’re not for everyone, and efforts to repurpose other drugs, or discover new ones, have not had much success.

Continue reading “How the Search for Covid-19 Treatments Faltered While Vaccines Sped Ahead”

The New York Times, January 29, 2021 (with Noah Weiland and Sharon LaFraniere)

Link

Johnson & Johnson, the only major drug maker developing a single-dose vaccine for Covid, announced on Friday that its shot provided strong protection against Covid-19, potentially offering another powerful tool in a desperate race against a worldwide rise in virus mutations.

But the results came with a significant cautionary note: The vaccine’s efficacy rate dropped from 72 percent in the United States to 57 percent in South Africa, where a highly contagious variant is driving most cases.

Continue reading “Johnson & Johnson’s Vaccine Offers Strong Protection but Fuels Concern About Variants”